Growth inhibition and apoptosis induction in ovarian cancer cells

International Journal of Oncology

Volumn 29, Issue 2, 2006, Pages 481-488

  Touma, Rania ^a   Kartarius, Sabine ^a   Harlozinska, Antonina ^b   Götz, Claudia ^a   Montenarh, Mathias ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Apoptosis; Gemcitabine; p53; Paclitaxel; irradiation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN P53; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; FEMALE; GENES, P53; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049180436     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.2.481     Document Type: Article

References (47)

1. Boente MP, Hurteau J, Rodriguez GC, Bast RC Jr and Berchuck A: The biology of ovarian cancer. Curr Opin Oncol 5: 900-907, 1993.
2. Du Bois A and Pfisterer J: Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer 15 (Suppl. 1): S42-S50, 2005. (Pubitemid 40696477)
3. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998. (Pubitemid 28446333)
4. Niedner H, Christen R, Lin X, Kondo A and Howell SB: Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160, 2001. (Pubitemid 33144883)
5. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 17: 1061-1070, 1999. (Pubitemid 29109340)
6. Wang LG, Liu XM, Kreis W and Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44: 355-361, 1999. (Pubitemid 29455579)
7. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
8. Harries M and Kaye SB: Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 10: 1715-1724, 2001. (Pubitemid 32827430)
9. Gershenson DM: Irinotecan in epithelial ovarian cancer. Oncology 16: 29-31, 2002.
10. Bookman MA: Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15 (Suppl. 1): S12-S17, 2005.
11. Cardenes H and Randall ME: Radiotherapy in epithelial ovarian cancer: state of the art. World Health Forum 10: 335-352, 2000.
12. Suzuki M, Saga Y, Tsukagoshi S, Tamura N and Sato I: Recurrent ovarian clear cell carcinoma: complete remission after radiation in combination with hyperthermia; a case study and in vitro study. Cancer Biother Radiopharm 15: 625-628, 2000. (Pubitemid 32038180)
13. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985, 1993. (Pubitemid 23267698)
14. Haupt S, Berger M, Goldberg Z and Haupt Y: Apoptosis - the p53 network. J Cell Sci 116: 4077-4085, 2003.
15. Wu Q, Kreienberg R and Runnebaum IB: Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro. J Cancer Res Clin Oncol 126: 139-144, 2000. (Pubitemid 30140213)
16. Bar JK and Harlozinska A: Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH1). Anticancer Res 20: 2975-2980, 2000.
17. Bar JK, Harlozinska A, Kartarius S, Montenarh M, Wyrodek E, Parkitna JMR, Kochman M and Ozyhar A: Temperature-sensitive ovarian carcinoma cell line (OvBH-1). Jpn J Cancer Res 93: 976-985, 2002. (Pubitemid 35154263)
18. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-682, 1970.
19. Harlow E, Crawford LV, Pim DC and Williamson NM: Monoclonal antibodies specific for the SV40 tumor antigens. J Virol 39: 861-869, 1981. (Pubitemid 11059884)
20. Ball RK, Siegl B, Quellhorst S, Brandner G and Braun DG: Monoclonal antibodies against simian virus 40 nuclear large tumour antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J 3: 1485-1491, 1984.
21. Saga Y, Suzuki M, Machida S, Ohwada M and Sato I: Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity. Oncology 62: 180-184, 2002. (Pubitemid 34253089)
22. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G and Bénard J: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 68: 67-74, 1996. (Pubitemid 26354581)
23. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B and Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684, 1993. (Pubitemid 23328959)
24. Douillard JY: Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. Clin Colorectal Cancer 5 (Suppl. 1): S34-S37, 2005.
25. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993. (Pubitemid 23315823)
26. Lavarino C, Delia D, Di Palma S, Zunino F and Pilotti S: p53 in drug resistance in ovarian cancer. Lancet 349: 1556-1556, 1997. (Pubitemid 27216387)
27. Debernardis D, Siré EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M and Broggini M: p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57: 870-874, 1997. (Pubitemid 27098011)
28. Reinecke P, Kalinski T, Mahotka C, Schmitz M, Dejosez M, Gabbert HE and Gerharz CD: Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status. Cancer Lett 222: 165-171, 2005. (Pubitemid 40603643)
29. 2/M check-point abrogators or altering the p53 status. Cancer Chemother Pharmacol 44: 217-227, 1999.
30. Faried A, Faried LS, Kimura H, Sohda M, Nakajima M, Miyazaki T, Kato H, Kanuma T and Kuwano H: Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer Chemother Pharmacol 57: 301-308, 2006.
31. Kaye SB: New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 78 (Suppl. 3): S1-S7, 1998.
32. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
33. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
34. Tsai JY, Iannitti DA and Safran H: Combined modality therapy for pancreatic cancer. Semin Oncol 30: 71-79, 2003. (Pubitemid 36999678)
35. Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ, Pinedo HM and Peters GJ: Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 83: 1069-1076, 2000.
36. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM and Peters GJ: Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17: 2190-2197, 1999. (Pubitemid 29318852)
37. Chang GC, Hsu SL, Tsai JR, Wu WJ, Chen CY and Sheu GT: Extracellular signal-regulated kinase activation and Bcl-2 down-regulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 502: 169-183, 2004.
38. Yaginuma Y and Westphal H: Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199, 1992.
39. Schlade-Bartusiak K, Sasiadek MM, Bar J, Urbschat S, Blin N, Montenarh M and Harlozinska A: Cytogenetic and molecular cytogenetic characterisation of the stable ovarian carcinoma cell line (OvBH-1). Cancer Genet Cytogenet 164: 10-15, 2006. (Pubitemid 41820350)
40. Wang Y and Prives C: Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91, 1995.
41. Stephen CW, Helminen P and Lane DP: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions. J Mol Biol 248: 58-78, 1995.
42. Vojtesek B, Bártek J, Midgley CA and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244, 1992.
43. Shaw P, Freeman J, Bovey R and Iggo R: Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12: 921-930, 1996. (Pubitemid 26072278)
44. Otvos L Jr, Hoffmann R, Xiang ZQ, O I, Deng HY, Wysocka M, Pease AM, Rogers ME, Blaszczyk-Thurin M and Ertl HCJ: A monoclonal antibody to a multiphosphorylated, conformational epitope at the carboxy-terminus of p53. Biochim Biophys Acta Mol Cell Res 1404: 457-474, 1998. (Pubitemid 28471931)
45. Milner JA, Cook A and Sheldon M: A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1: 453-455, 1987. (Pubitemid 17159261)
46. Gannon JV, Greaves R, Iggo R and Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602, 1990.
47. Banks L, Matlashewski G and Crawford LV: Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534, 1986. (Pubitemid 16033297)